TYK Medicines, Inc. (Chinese name: 浙江同源康醫藥股份有限公司) released its updated Articles of Association dated October 2025. According to the document, TYK Medicines, Inc. is a joint stock limited company sponsored by Tetranov Pharmaceutical (Zhengzhou) Co., Ltd. and Pivot Pharma Tech (Shanghai) Co., Ltd. and has been listed on The Stock Exchange of Hong Kong Limited since August 20, 2024.
The Articles of Association specify that the Company’s registered capital is RMB380.065818 million, with a total of 380,065,818 ordinary shares issued. Among them, 4,608,000 are unlisted shares, while 375,457,818 are H Shares offered and traded overseas. The document further clarifies rules on capital increases or reductions, share issuance, and the procedure for share repurchases.
The governance framework is outlined in detail. The Company’s Board of Directors consists of ten members, including four independent non-executive directors. The Board has established committees such as the Audit Committee (exercising supervisory functions), Nomination Committee, and Remuneration and Appraisal Committee to enhance oversight. The Articles of Association also delineate shareholder rights and procedures for convening general meetings, addressing matters like dividend distribution and significant transactions.
Furthermore, the document covers the Company’s financial and accounting systems, including guidelines on internal audits, selection of accounting firms, and a comprehensive approach to profit distribution. It stipulates that profit distributions should be made in accordance with statutory requirements to protect shareholders’ interests. It also details the procedures for corporate reorganization, including the rules governing mergers, divisions, and possible scenarios of liquidation.
This latest version of the Articles of Association underscores TYK Medicines, Inc.’s emphasis on transparent governance, protection of shareholder rights, and clear operational procedures. All information herein is based entirely on the announcement document.